<DOC>
	<DOCNO>NCT02378714</DOCNO>
	<brief_summary>Persons struggle depression smoke high rate experience low quit rate treatment . The best way improve cessation treatment underserved population remain unknown . The propose trial test whether combination varenicline behavioral mood management treatment enhance long-term abstinence depress smoker , , whether treatment achieves effect address unique psychological factor appear maintain tobacco dependence smoker .</brief_summary>
	<brief_title>Behavioral Activation Varenicline Smoking Cessation Depressed Smokers</brief_title>
	<detailed_description>Upwards 43 % person major depressive disorder ( MDD ) daily smoker likely smoke heavily , show great tobacco dependence , suffer severe withdrawal , experience low quit rate smoker without MDD . Little known treatment strategy might optimize smoke cessation smoker MDD almost randomize clinical trial exclude smoker . This project answer many prominent largely unanswered call last decade address tobacco dependence person mental health disorder , especially major depressive disorder ( MDD ) . Using double-blind , placebo-controlled , randomized design , investigator evaluate efficacy behavioral activation smoke cessation ( BASC ) plus varenicline treating tobacco dependence smoker current recent ( past two year ) MDD . Five hundred seventy-six daily ( â‰¥1 cigarettes/day ) smoker randomize receive 12 week one four treatment : 1 ) Standard behavioral cessation treatment ( ST ) + placebo ; 2 ) Behavioral activation integrate ST ( BASC ) + placebo ; 3 ) ST + varenicline ; 4 ) BASC + varenicline . Both BASC ST administer eight 45 minute session , occur weekly first four week biweekly final eight week . Randomization stratify clinical site ( Northwestern , University Pennsylvania ) , gender , severity depressive symptom ( minimal/mild vs. moderate/severe ) . The primary outcome carbon monoxide ( CO ) verify 7-day point prevalence abstinence 24-weeks post-quit . Additional aim include assess adverse event rate varenicline placebo arm , test mediation treatment effect anhedonia , cognitive function ( attention memory ) , cigarette reward value , crave withdrawal . This randomize controlled trial first adequately powered trial BASC population ; first trial evaluate varenicline among community sample smoker MDD ; first trial ass main combined effect two treatment .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Inclusion criterion : 1. adult ( 18 year age old ) daily cigarette smoker ( 1+ cigarette per day ) 2. meet criterion current lifetime MDD without psychotic feature 3. willing acquire personal email address access camera phone method submission therapy practice assignment 4. speak , read , write fluently English 5. able provide write informed consent 6. intend reside geographic area &gt; 8 month 7. woman childbearing potential must agree use medically acceptable method birth control abstain sexual intercourse time take study medication least one month medication period end . Exclusion criterion : 1. current enrollment plan enroll another smoking cessation program next 8 month 2. regular ( daily ) use ecigarettes , chew tobacco , snuff , snus , tobacco product 3. current use plan use nicotine replacement therapy smoke cessation medication within next 8 month 4. medication indicate bipolar psychotic disorder prescribe bipolar psychotic disorder 5. pregnant plan become pregnant within next 8 month , breast feeding 6. history seizure current seizure disorder without medication 7. history severe ( stage IV V ) chronic kidney disease include current prior end stage renal disease either hemodialysis peritoneal dialysis prior renal transplant 8. prior solid organ transplant prior hematopoietic stem cell transplant 9. alcohol consumption exceed 28 drink per week 10. cirrhosis endstage liver disease 11. systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg two reading symptomatic uncontrolled stage II hypertension 12. unstable cardiovascular disease within 3 month prior baseline cardiovascular disease require hospitalization 13. prior hospitalization heart failure 14. previous allergic reaction varenicline 15. high suicide risk base Columbia Suicide Severity Rating Scale 16. lifetime bipolar psychotic disorder determine either selfreport clinical interview</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Smoking Cessation</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Nicotine Dependence</keyword>
	<keyword>Varenicline</keyword>
	<keyword>Behavioral Activation Therapy</keyword>
	<keyword>Cigarette Smoking</keyword>
</DOC>